15.50

2.15% -0.34

Monte Rosa Therapeutics Inc (GLUE)

Overview News Price History Option Chain Financials Why GLUE Down? Discussions Forecast

Monte Rosa Therapeutics Inc stock is traded at $15.50, with a volume of 509.19K. It is down -2.15% in the last 24 hours and down -33.93% over the past month. Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).

Previous Close:

$15.84

Open:

$15.72

24h Volume:

509.19K

Relative Volume:

0.38

Market Cap:

$1.32B

Revenue:

$42.95M

Net Income/Loss:

$-130.01M

P/E Ratio:

-9.5221

EPS:

-1.6278

Net Cash Flow:

$-19.66M

1W Performance:

-2.39%

1M Performance:

-33.93%

6M Performance:

-13.50%

1Y Performance:

+256.32%

1-Day Range:

$15.37

$15.83

1-Week Range:

$15.37

$16.27

52-Week Range:

$4.30

$25.77

Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile

Name

Monte Rosa Therapeutics Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

617-949-2643

Address

321 HARRISON AVENUE, BOSTON

Employee

161

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

GLUE's Discussions on Twitter

Compare GLUE vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GLUE Monte Rosa Therapeutics Inc	15.50	1.36B	42.95M	-130.01M	-19.66M	-1.6278
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Feb-15-24	Initiated	Wedbush	Outperform
Jan-03-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Oct-13-22	Initiated	UBS	Buy
Aug-15-22	Initiated	Jefferies	Buy
Apr-28-22	Initiated	Credit Suisse	Neutral
Feb-10-22	Initiated	Wells Fargo	Equal Weight
Oct-14-21	Initiated	SVB Leerink	Mkt Perform

View All

Monte Rosa Therapeutics Inc Stock (GLUE) Latest News

Aug 14, 2026

Monte Rosa Therapeutics (GLUE) holders report sub‑5% stakes in amended 13G - Stock Titan

Aug 14, 2026

Monte Rosa Therapeutics (GLUE): Vestal Point discloses 4.6M-share, 5.4% ownership - Stock Titan

Aug 14, 2026

Aug 12, 2026

Industry Analysts Just Upgraded Their Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Revenue Forecasts By 21% - simplywall.st

Aug 12, 2026

Aug 11, 2026

Why Monte Rosa Therapeutics (GLUE) Is Back In Focus After Its Latest Update - Sahm

Aug 11, 2026

Aug 10, 2026

Analysts Are Upgrading Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) After Its Latest Results - simplywall.st

Aug 10, 2026

Aug 09, 2026

What Monte Rosa Therapeutics (GLUE)'s Swing From Profit To Deeper Losses Means For Shareholders - simplywall.st

Aug 09, 2026

Aug 08, 2026

Monte Rosa Therapeutics (NASDAQ:GLUE) Announces Earnings Results - MarketBeat

Aug 08, 2026

MONTE ROSA THERAPEUTICS, INC. : WELLS FARGO CUTS TARGET PRICE TO $27 FROM $29 - webull.com

Aug 08, 2026